

# APOLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035

10<sup>th</sup> February 2026

The Secretary,  
Bombay Stock Exchange Ltd (BSE)  
Phiroze Jheejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001.  
**Scrip Code – 508869**  
**ISIN INE437A01024**

The Secretary,  
National Stock Exchange,  
Exchange Plaza, 5th Floor  
Plot No.C/1, 'G' Block  
Bandra – Kurla Complex  
Bandra (E)  
Mumbai – 400 051.  
**Scrip Code- APOLLOHOSP**  
**ISIN INE437A01024**

Dear Sir/Madam,

### **Sub: Outcome of the Board Meeting**

This has reference to our letters dated 16<sup>th</sup> January and 5<sup>th</sup> February 2026, regarding the captioned subject. The Board at its meeting held today transacted the following items of business.

### **Financial Results**

1. Unaudited financial results (both standalone and consolidated) of the Company for the three and nine months ended 31st December 2025, which have been subjected to Limited Review by the Statutory Auditors of the Company – as Annexure I.
2. Copy of the Limited Review Report of the Statutory Auditors for the corresponding period.
3. The unaudited financial results will also be published in the newspapers, in the format prescribed under Regulation 47 of the Listing Regulations.
4. The said documents are being posted on the website of the Company i.e., [www.apollohospitals.com](http://www.apollohospitals.com).

### **Interim Dividend**

The Board of Directors declared an interim dividend of Rs.10/- per share (200% of face value of Rs.5/- per share) for the financial year ending 31st March 2026, on the paid up equity shares, out of the profits of the Company.

# APOLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



## Record Date

The Board has fixed the record date as 16<sup>th</sup> February 2026 for the purpose of payment of Interim Dividend and the said Interim Dividend will be paid to the equity shareholders, whose names appear in the Register of Members/ Beneficial Owners of the Company as on 16<sup>th</sup> February 2026.

## Dividend Payment Date

The said interim dividend would be paid to all the equity shareholders of the Company on or before 27<sup>th</sup> February 2026.

You are requested to kindly take note of the same.

The meeting of the Board of Directors commenced at 2.45 p.m. and concluded at ..... 5.40 P.M.

Please take note of the same in your records.

Thanking You

Yours faithfully  
For APOLLO HOSPITALS ENTERPRISE LIMITED

A handwritten signature in blue ink, appearing to read 'S.M. Krishnan'.

S.M. KRISHNAN  
Sr. VICE PRESIDENT – FINANCE  
AND COMPANY SECRETARY

# Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com  
Website: www.apollohospitals.com

## Statement of unaudited standalone financial results for the three and nine months ended December 31, 2025

(Rs. in Million)

Particulars	Three months ended 31/12/2025	Preceeding three months ended 30/09/2025	Corresponding three months ended 31/12/2024	Year to date figures for current period ended 31/12/2025	Year to date figures for previous period ended 31/12/2024	Previous year ended 31/03/2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1 Income</b>						
(a) Revenue from operations	23,637	23,561	20,548	68,877	61,268	82,021
(b) Other income	1,080	1,411	1,079	2,816	2,561	3,477
<b>Total income (a + b)</b>	<b>24,717</b>	<b>24,972</b>	<b>21,627</b>	<b>71,693</b>	<b>63,829</b>	<b>85,498</b>
<b>2 Expenses</b>						
(a) Cost of materials consumed	6,117	6,112	5,693	18,126	16,864	22,484
(b) Employee benefits expense	4,101	4,312	3,935	12,450	11,866	15,968
(c) Finance costs	617	579	620	1,784	1,909	2,540
(d) Depreciation and amortisation expenses	1,268	1,224	1,084	3,724	3,196	4,494
(e) Other expenses	7,484	7,208	5,802	20,976	17,309	23,127
<b>Total expenses</b>	<b>19,587</b>	<b>19,435</b>	<b>17,134</b>	<b>57,060</b>	<b>51,144</b>	<b>68,613</b>
<b>3 Profit before tax and exceptional items (1) - (2)</b>	<b>5,130</b>	<b>5,537</b>	<b>4,493</b>	<b>14,633</b>	<b>12,685</b>	<b>16,885</b>
<b>4 Exceptional item (Refer note 6)</b>	<b>(114)</b>	<b>-</b>	<b>-</b>	<b>(114)</b>	<b>-</b>	<b>-</b>
<b>5 Profit before tax (3) + (4)</b>	<b>5,016</b>	<b>5,537</b>	<b>4,493</b>	<b>14,519</b>	<b>12,685</b>	<b>16,885</b>
<b>6 Tax expense</b>						
Current tax	1,066	1,232	1,051	3,191	3,063	4,055
Deferred tax	115	106	26	225	(7)	(133)
<b>7 Profit after tax for the period / year (5) - (6)</b>	<b>3,835</b>	<b>4,199</b>	<b>3,416</b>	<b>11,103</b>	<b>9,629</b>	<b>12,963</b>
<b>8 Other comprehensive income/(loss)</b>						
Items that will not be reclassified to profit or loss						
(a) Remeasurement gains/(losses) on defined benefit plans	(32)	(108)	(33)	(64)	2	3
(b) Income tax relating to items that will not be reclassified to profit or loss	8	27	8	16	(1)	(1)
<b>Total other comprehensive income/ (loss)</b>	<b>(24)</b>	<b>(81)</b>	<b>(25)</b>	<b>(48)</b>	<b>1</b>	<b>2</b>
<b>9 Total comprehensive income for the period/year (7) + (8)</b>	<b>3,811</b>	<b>4,118</b>	<b>3,391</b>	<b>11,055</b>	<b>9,630</b>	<b>12,965</b>
<b>10 Paid-up equity share capital (Face value Rs.5/- per share)</b>				719	719	719
<b>11 Reserves (excluding Revaluation reserves)</b>				96,240	84,576	86,623
<b>12 Earnings per equity share ('EPS') of Rs.5/- each</b>				*77.22	*66.97	90.15
Basic and diluted EPS for the period/year (Rs.)	*26.67	*29.20	*23.76			
<b>13 Additional Information :-</b>						
Earnings before finance costs, tax, depreciation and amortization, other income, exceptional items (EBITDA) (refer foot note)	5,935	5,929	5,118	17,325	15,229	20,442

\*Not annualised

**Foot note:**

The Company has presented EBITDA additionally as part of standalone financial results.

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY  
Managing Director

# **Apollo Hospitals Enterprise Limited**

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website: [www.apollohospitals.com](http://www.apollohospitals.com)

## **NOTES TO THE UNAUDITED STANDALONE FINANCIAL RESULTS:**

1. The unaudited standalone financial results ("the statement") of **Apollo Hospitals Enterprise Limited** ("the Company") for the three and nine months ended December 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 10, 2026. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the financial results for the three and nine months ended December 31, 2025.
2. The statement has been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.
3. The Company's business activity primarily falls within a single reportable business segment namely "Healthcare Services" and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind As 108- "Segment Reporting".
4. The Board at its meeting held on 30th June 2025, subject to necessary approvals considered and approved a Composite Scheme of Arrangement amongst, the Company (AHEL), Apollo Healthco Limited ("Transferor Company 1" or "AHL") - Keimed Private Limited ("Transferor Company 2"), and Apollo Healthtech Limited ("Resultant Company") and their respective shareholders and creditors ("Scheme"), in accordance with the provisions of Sections 230-232 and other applicable provisions of the Companies Act, 2013, the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular dated June 20, 2023 (SEBI/HO/CFD/POD-2/P/CIR/2023/93), and other applicable rules, regulations, and circulars issued by regulatory authorities.

The Scheme inter alia provides for demerger of identified business undertaking (as defined in the scheme) primarily representing the Omni channel pharmacy distribution business and digital health platform business of the Company into the Resultant Company; the amalgamation of "Transferor Company 1" with and into the Resultant Company; the amalgamation of "Transferor Company 2" with and into the Resultant Company; and the consequent listing of the equity shares of the Resultant Company on the National Stock Exchange of India Limited and Bombay Stock Exchange Limited and admission to trading.

National Stock Exchange of India Limited and BSE Limited have issued letters dated December 23 and December 24, 2025 respectively, under regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Subsequent to the receipt of such letters, the Company has filed an application before the National Company Law Tribunal seeking approval of the scheme.

For APOLLO HOSPITALS ENTERPRISE LTD

  
SUNEETA REDDY  
Managing Director

# **Apollo Hospitals Enterprise Limited**

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website: [www.apollohospitals.com](http://www.apollohospitals.com)

5. The Board also approved a Business Framework Agreement dated June 30, 2025, between AHEL and AHL to establish a framework of rights and restrictions pursuant to which each party shall: (i) independently pursue its respective businesses; and (ii) collaborate and cooperate with the other for mutual benefit. Upon effectiveness of the Scheme, the rights and obligations of AHL under this agreement will be binding on the Resultant Company.
6. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty nine existing labour laws into a unified framework governing employee benefits during employment and post-employment.

The Company has assessed the financial implications of these changes, which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs 114 million. Considering the materiality and regulatory driven non-recurring nature of this impact, the Company has presented the same as Exceptional item in the Statement. The Company continues to monitor the finalisation of Central and State Rules, as well as Government clarifications on other aspects of the Labour Codes, and will incorporate appropriate accounting treatment based on these developments as required.

7. The Board of Directors of the Company has declared an interim dividend of Rs.10/- per share (200%) of face value of Rs.5/- each for the financial year 2025-2026.
8. The aforesaid financial results are also available on the Company's website ([www.apollohospitals.com](http://www.apollohospitals.com)).

For **APOLLO HOSPITALS ENTERPRISE LIMITED**

Place: Chennai  
Date: February 10, 2026

**Dr. Prathap C Reddy**  
*Executive Chairman*

For APOLLO HOSPITALS ENTERPRISE LTD

  
SUNEETA REDDY  
Managing Director

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF APOLLO HOSPITALS ENTERPRISE LIMITED

1. We have reviewed the accompanying Statement of unaudited Standalone Financial Results of **Apollo Hospitals Enterprise Limited** ("the Company") for the three months and nine months ended December 31, 2025 (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



*Nachiappan Subramanian*  
**Nachiappan Subramanian**  
Partner  
Membership No. 218727  
UDIN: 26218727ESENXXXX4417

Place: Chennai  
Date: February 10, 2026

**Apollo Hospitals Enterprise Limited**

Corporate Identity Number : L85110TN1979PLC008039

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaiapuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website: [www.apollohospitals.com](http://www.apollohospitals.com)

**Statement of unaudited consolidated financial results for the three months and nine months ended December 31, 2025**

(Rs. in Million)

Particulars	Three months ended 31/12/2025	Preceeding three months ended 30/09/2025	Corresponding three months ended 31/12/2024	Year to date figures for current period ended 31/12/2025	Year to date figures for previous period ended 31/12/2024	Previous year ended 31/03/2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1 Income</b>						
(a) Revenue from operations	64,774	63,035	55,269	1,86,230	1,62,018	2,17,940
(b) Other income	528	547	638	1,477	1,392	2,003
<b>Total Income (a + b)</b>	<b>65,302</b>	<b>63,582</b>	<b>55,907</b>	<b>1,87,707</b>	<b>1,63,410</b>	<b>2,19,943</b>
<b>2 Expenses</b>						
(a) Cost of materials consumed	7,446	7,787	6,256	22,634	20,600	27,544
(b) Purchases of stock-in-trade	26,631	24,647	22,920	74,433	63,131	85,567
(c) Changes in inventories of stock-in-trade	(253)	2	(169)	(331)	83	(11)
(d) Employee benefits expense	7,490	7,667	6,864	22,283	20,446	27,692
(e) Finance costs	1,126	1,096	1,098	3,305	3,437	4,585
(f) Depreciation and amortisation expense	2,192	2,178	1,846	6,517	5,465	7,575
(g) Other expenses	13,807	13,521	11,783	39,628	35,237	46,930
<b>Total expenses</b>	<b>58,439</b>	<b>56,898</b>	<b>50,598</b>	<b>1,68,469</b>	<b>1,48,399</b>	<b>1,99,882</b>
<b>3 Profit before share of profit/(loss) in associates / joint ventures and exceptional items (1) - (2)</b>	<b>6,863</b>	<b>6,684</b>	<b>5,309</b>	<b>19,238</b>	<b>15,011</b>	<b>20,061</b>
4 Share of profit/(loss) of associates /joint ventures	149	63	53	348	225	330
<b>5 Profit before tax and exceptional items (3) + (4)</b>	<b>7,012</b>	<b>6,747</b>	<b>5,362</b>	<b>19,586</b>	<b>15,236</b>	<b>20,391</b>
6 Exceptional item (Refer note 6)	(192)	-	-	(192)	-	-
<b>7 Profit before tax (5) + (6)</b>	<b>6,820</b>	<b>6,747</b>	<b>5,362</b>	<b>19,394</b>	<b>15,236</b>	<b>20,391</b>
<b>8 Tax expenses</b>						
Current tax	1,470	1,615	1,345	4,333	4,073	5,263
Deferred tax	187	192	223	548	257	77
<b>9 Profit after tax for the period/year (7) - (8)</b>	<b>5,163</b>	<b>4,940</b>	<b>3,794</b>	<b>14,513</b>	<b>10,906</b>	<b>15,051</b>
<b>10 Other Comprehensive Income</b>						
Items that will not be reclassified to Profit or Loss						
Remeasurement gains / (losses) on defined benefit plan	(9)	(92)	(34)	(40)	(48)	(84)
Equity instruments through other comprehensive income	-	745		745	-	(2)
Income tax relating to items that will not be reclassified to profit or loss	3	(96)	(1)	(95)	8	17
Items that will be reclassified to Profit or Loss						
Exchange differences in translating the financial statements of foreign operations	4	11	6	15	7	6
<b>Total other comprehensive income/ (loss)</b>	<b>(2)</b>	<b>568</b>	<b>(29)</b>	<b>625</b>	<b>(33)</b>	<b>(63)</b>
<b>11 Total comprehensive income for the period/year (9) + (10)</b>	<b>5,161</b>	<b>5,508</b>	<b>3,765</b>	<b>15,138</b>	<b>10,873</b>	<b>14,988</b>
<b>Profit for the period/ year attributable to:</b>						
Owners of the parent	5,023	4,772	3,723	14,123	10,563	14,459
Non-controlling interest	140	168	71	390	343	592
<b>Other comprehensive income/ (loss) for the period/ year attributable to:</b>						
Owners of the parent	(1)	565	(28)	624	(25)	(50)
Non-controlling interest	(1)	3	(1)	1	(8)	(13)
<b>Total comprehensive income for the period/ year attributable to:</b>						
Owners of the parent	5,022	5,337	3,695	14,747	10,538	14,409
Non-controlling interest	139	171	70	391	335	579
<b>12 Paid-up equity share capital (Face value Rs.5/- per share)</b>						
Reserves (excluding revaluation reserves)				719	719	719
				95,472	78,216	81,326
<b>13 Earnings per equity share ('EPS') of Rs.5/- each</b>						
Basic and diluted EPS for the period/year (Rs.)	34.94	*33.19	*25.89	*98.23	*73.46	100.56

\*Not annualised

SUNEETA REDDY  
Managing Director

# Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com  
Website: www.apollohospitals.com

## Consolidated Segment wise Revenue, Results, Segment Assets and Segment Liabilities

(Rs. in Million)

Particulars	Three months ended 31/12/2025	Preceeding three months ended 30/09/2025	Corresponding three months ended 31/12/2024	Year to date figures for current period ended 31/12/2025	Year to date figures for previous period ended 31/12/2024	Previous year ended 31/03/2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Segment revenue</b>						
a) Healthcare services	32,253	32,173	28,029	94,164	83,770	1,12,201
b) Retail health and diagnostics	4,668	4,739	3,896	13,758	11,596	15,535
c) Digital health and pharmacy distribution	28,275	26,605	23,524	79,599	67,167	90,930
d) Others	13	13	12	39	36	48
<b>SUB - TOTAL</b>	<b>65,209</b>	<b>63,530</b>	<b>55,461</b>	<b>1,87,560</b>	<b>1,62,569</b>	<b>2,18,714</b>
Less : Intersegmental revenue	435	495	192	1,330	551	774
<b>Income from operations</b>	<b>64,774</b>	<b>63,035</b>	<b>55,269</b>	<b>1,86,230</b>	<b>1,62,018</b>	<b>2,17,940</b>
<b>2. Segment results</b>						
a) Healthcare services	6,243	6,296	5,315	18,158	16,030	21,295
b) Retail health and diagnostics	117	136	37	324	181	300
c) Digital health and pharmacy distribution	1,080	859	436	2,631	897	1,127
d) Others	21	(58)	(19)	(47)	(52)	(79)
<b>SUB - TOTAL</b>	<b>7,461</b>	<b>7,233</b>	<b>5,769</b>	<b>21,066</b>	<b>17,056</b>	<b>22,643</b>
Less: (i) Finance cost	1,126	1,096	1,098	3,305	3,437	4,585
Add: (ii) Other un-allocable income, (net of expenditure)	528	547	638	1,477	1,392	2,003
Add: (iii) Share of profit/(loss) of associates / joint ventures	149	63	53	348	225	330
Add: (iv) Exceptional item	(192)	-	-	(192)	-	-
<b>Profit Before Tax</b>	<b>6,820</b>	<b>6,747</b>	<b>5,362</b>	<b>19,394</b>	<b>15,236</b>	<b>20,391</b>
<b>3. Capital employed</b>						
<b>a) Healthcare services *</b>						
Segment assets	1,36,651	1,31,799	1,24,651	1,36,651	1,24,651	1,27,403
Segment liabilities	(43,559)	(43,180)	(40,380)	(43,559)	(40,380)	(41,107)
<b>b) Retail health and diagnostics</b>						
Segment assets	13,992	14,188	12,537	13,992	12,537	13,277
Segment liabilities	(11,636)	(11,673)	(10,707)	(11,636)	(10,707)	(11,005)
<b>c) Digital health and pharmacy distribution</b>						
Segment assets	31,937	31,677	26,094	31,937	26,094	29,629
Segment liabilities	(9,425)	(10,168)	(13,485)	(9,425)	(13,485)	(10,206)
<b>d) Others</b>						
Segment assets	264	269	286	264	286	280
Segment liabilities	(182)	(181)	(177)	(182)	(177)	(179)
<b>e) Unallocated</b>						
Segment assets	41,621	41,570	30,449	41,622	30,449	35,984
Segment liabilities	(58,655)	(58,767)	(46,020)	(58,655)	(46,020)	(57,547)
<b>Total</b>	<b>1,01,009</b>	<b>95,534</b>	<b>83,247</b>	<b>1,01,010</b>	<b>83,247</b>	<b>86,529</b>
* Includes capital employed in various hospital projects under construction	11,405	10,413	10,952	11,405	10,952	9,210

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY  
Managing Director



# **Apollo Hospitals Enterprise Limited**

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website: [www.apollohospitals.com](http://www.apollohospitals.com)

## **NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS:**

1. The unaudited consolidated financial results ("the statement") of **Apollo Hospitals Enterprise Limited** ("the Company") for the three and nine months ended December 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 10, 2026. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the unaudited consolidated financial results for the three and nine months ended December 31, 2025.
2. The statement has been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.
3. The Board at its meeting held on 30th June 2025, subject to necessary approvals considered and approved a Composite Scheme of Arrangement amongst, the Company (AHEL), Apollo Healthco Limited ("Transferor Company 1" or "AHL") – Keimed Private Limited ("Transferor Company 2"), and Apollo Healthtech Limited ("Resultant Company") and their respective shareholders and creditors ("Scheme"), in accordance with the provisions of Sections 230–232 and other applicable provisions of the Companies Act, 2013, the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular dated June 20, 2023 (SEBI/HO/CFD/POD-2/P/CIR/2023/93), and other applicable rules, regulations, and circulars issued by regulatory authorities.

The Scheme inter alia provides for demerger of identified business undertaking (as defined in the scheme) primarily representing the Omni channel pharmacy distribution business and digital health platform business of the Company into the Resultant Company; the amalgamation of "Transferor Company 1" with and into the Resultant Company; the amalgamation of "Transferor Company 2" with and into the Resultant Company; and the consequent listing of the equity shares of the Resultant Company on the National Stock Exchange of India Limited and Bombay Stock Exchange Limited and admission to trading.

National Stock Exchange of India Limited and BSE Limited have issued letters dated December 23 and December 24, 2025 respectively, under regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Subsequent to the receipt of such letters, the Group has filed an application before the National Company Law Tribunal seeking approval of the scheme.

4. The Board also approved a Business Framework Agreement dated June 30, 2025, between AHEL and AHL to establish a framework of rights and restrictions pursuant to which each party shall: (i) independently pursue its respective businesses; and (ii) collaborate and cooperate with the other for mutual benefit. Upon effectiveness of the Scheme, the rights and obligations of AHL under this agreement will be binding on the Resultant Company.

For APOLLO HOSPITALS ENTERPRISE LTD

  
SUNEETA REDDY  
Managing Director

# **Apollo Hospitals Enterprise Limited**

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website: [www.apollohospitals.com](http://www.apollohospitals.com)

5. The Honourable High Court of Karnataka on October 8, 2021 set aside the order of the Revenue Department, State of Karnataka ("Revenue Department") initiated earlier against a subsidiary alleging non-compliance of certain conditions associated with the allotment of land to the subsidiary and had directed the Revenue Department to reconsider and dispose the matter. The Revenue Department had issued a show cause notice dated February 9, 2022 seeking explanations as to why the original order needs to be withdrawn, for which the subsidiary had filed a detailed response explaining how there are no violations of the conditions relating to the allotment of the land. Based on an external legal opinion received, the subsidiary has adequate grounds to demonstrate compliance with applicable conditions and therefore is of the opinion that the matter would be settled in its favour.
6. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty nine existing labour laws into a unified framework governing employee benefits during employment and post-employment.

The Group has assessed the financial implications of these changes, which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs 192 million. Considering the materiality and regulatory-driven non-recurring nature of this impact, the Group has presented the same as Exceptional Items in the statement. The Group continues to monitor the finalisation of Central and State Rules, as well as Government clarifications on other aspects of the Labour Codes, and will incorporate appropriate accounting treatment based on these developments as required.

7. The Board of Directors of the Company has declared an interim dividend of Rs.10/- per share (200%) of face value of Rs.5/- each for the financial year 2025-2026.
8. The aforesaid financial results are also available on the Company's website ([www.apollohospitals.com](http://www.apollohospitals.com)).

**For APOLLO HOSPITALS ENTERPRISE LIMITED**

Place: Chennai

Date: February 10, 2026

**Dr. Prathap C Reddy**

*Executive Chairman*

For APOLLO HOSPITALS ENTERPRISE LTD

  
SUNEETA REDDY  
Managing Director

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM  
CONSOLIDATED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
Apollo Hospitals Enterprise Limited**

1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of **Apollo Hospitals Enterprise Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income (net) of its associates and joint ventures for the three months and nine months ended December 31, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

<b>Name of the Company</b>	<b>Relationship</b>
Apollo Hospitals Enterprise Limited (AHEL)	Parent
Apollo Home Healthcare Limited (AHHL)	Subsidiary
AB Medical Centres Limited	Subsidiary
Samudra Health Care Enterprises Limited	Subsidiary
Imperial Hospitals & Research Centre Limited	Subsidiary
Apollo Hospitals (UK) Limited	Subsidiary



<b>Name of the Company</b>	<b>Relationship</b>
Apollo Health and Lifestyle Limited (AHLL)	Subsidiary
Apollo Nellore Hospital Limited	Subsidiary
Sapien Bio-sciences Private Limited	Subsidiary
Apollo Hospitals International Limited (AHIL)	Subsidiary
Apollo Lavasa Health Corporation Limited	Subsidiary
Apollo Rajshree Hospital Private Limited (ARHPL)	Subsidiary
Future Parking Private Limited	Subsidiary
Total Health	Subsidiary
Apollo Hospitals Singapore Pte Limited	Subsidiary
Assam Hospitals Limited (Assam)	Subsidiary
Apollomedics International Lifesciences Limited	Subsidiary
Apollo Multi Specialty Hospitals Limited (AMSHL)	Subsidiary
Apollo HealthCo Limited (AHL)	Subsidiary
Apollo Hospitals North Limited	Subsidiary
Kerala First Health Services Private Limited (KFHS)	Subsidiary
Health Axis Private Limited (HAPL)	Subsidiary
Apollo Health Axis Inc (w.e.f 12 November 2025)	Subsidiary of HAPL
Apollo Hospitals Jammu and Kashmir Limited	Subsidiary
Apollo Hospitals Worli LLP	Subsidiary
Apollo Healthtech Limited (w.e.f. 10 June 2025)	Subsidiary
Apollo Gleneagles PET-CT Private Limited (w.e.f 30 September 2025)	Subsidiary
Alliance Dental Care Limited	Subsidiary of AHLL
Apollo Dialysis Private Limited	Subsidiary of AHLL
Apollo Sugar Clinics Limited	Subsidiary of AHLL
Apollo Speciality Hospitals Limited	Subsidiary of AHLL
AHLL Diagnostics Limited	Subsidiary of AHLL
AHLL Risk Management Private Limited	Subsidiary of AHLL
Care Diagnostics Private Limited (w.e.f. 1 February 2025)	Subsidiary of AHLL
Sobhagya Hospital and Research Centre Private Limited	Subsidiary of ARHPL
Apollo Fertility Centre Private Limited (Formerly known as Surya Fertility Centre Private Limited)	Stepdown Subsidiary of AHLL
Apollo Spectra Centres Private Limited (Formerly known as Kshema Healthcare Private Limited)	Stepdown Subsidiary of AHLL
Apollo Cradle and Children Hospital Private Limited	Stepdown Subsidiary of AHLL
Apollo 24/7 Insurance Services Limited	Subsidiary of AHL
Asclepius Hospitals and Healthcare Private Limited	Subsidiary of Assam
Apollo CVHF Limited	Subsidiary of AHIL
Baalayam Healthcare Private Limited	Subsidiary of KFHS
Family Health Plan Insurance (TPA) Limited	Associate



<b>Name of the Company</b>	<b>Relationship</b>
Indraprastha Medical Corporation Limited	Associate
Stemcyte India Therapeutics Private Limited	Associate
Apollo Medical Private Limited (AMPL)	Associate of AHL
Apollo Pharmacies Limited	Subsidiary of AMPL
Apollo Pharmalogistics Private Limited	Subsidiary of AMPL
ApoKos Rehab Private Limited	Joint venture
Nexify Health Private Limited	Joint venture of HAPL

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We draw attention to Note 5 to the Statement in respect of proceedings initiated against the subsidiary, Imperial Hospitals & Research Centre Limited, by the Government of Karnataka. Our conclusion on the Statement is not modified in respect of this matter.
7. We did not review the interim financial results/financial information of 26 subsidiaries included in the consolidated unaudited financial results, whose interim financial results/financial information reflect total revenues of Rs. 5,013 million and Rs. 14,627 million for the three months and nine months ended December 31, 2025 respectively, total net profit after tax of Rs. 346 million and Rs. 930 million for the three months and nine months ended December 31, 2025 respectively and total comprehensive income (net) of Rs. 344 million and Rs. 929 million for the three and nine months ended December 31, 2025 respectively, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of net profit after tax of Rs. 142 million and Rs. 327 million for the three months and nine months ended December 31, 2025 respectively and total comprehensive income (net) of Rs. 143 million and Rs. 332 million for the three months and nine months ended December 31, 2025 respectively, as considered in the Statement, in respect of 1 joint ventures and 5 associates (including 2 subsidiaries of 1 associate), whose interim financial results/financial information have not been reviewed by us. These interim financial results/financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.



8. The consolidated unaudited financial results includes the interim financial results/financial information of 7 subsidiaries which have not been reviewed by their auditors, whose interim financial results/financial information reflect total revenue of Rs. 31 million and Rs. 90 million for the three months and nine months ended December 31, 2025 respectively, total Profit after tax of Rs. 47 million and Rs. 11 million for the three months and nine months ended December 31, 2025 respectively and total comprehensive income(net) of Rs. 46 million and Rs. 6 million for the three months and nine months ended December 31, 2025 respectively as considered in the Statement. The consolidated unaudited financial information also includes the Group's share of profit after tax of Rs. Nil and Rs. Nil for the three months and nine months ended December 31, 2025 respectively and total comprehensive income of Rs. Nil and Rs. Nil for the three months and nine months ended December 31, 2025 respectively, as considered in the Statement, in respect of 1 associate, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial results/financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial results/financial information certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



*Nachiappan Subramanian*  
Partner  
Membership No. 218727  
UDIN: 26218727GUDAPO1689

Place: Chennai  
Date: February 10, 2026

## Apollo Hospitals announces Q3FY26 results

**Strong growth in Revenue and EBITDA across all 3 business verticals, and on a consolidated basis**

**Continues capacity growth momentum with Phase 1 launch of 250-bed quaternary capability in Pune**

**Achieves key clinical excellence milestones; Demonstrates improved performance in CONGO-T specialties and high-complexity work**

**Increased traction from International Patient Services vertical**

**Strengthened Payor Mix driven by consumer preference and continuous engagement with Health Insurance companies.**

**Apollo Hospitals declares an Interim Dividend of Rs 10 per share**

### **Launched Quaternary Capability in Pune**

Apollo Hospitals launched a cutting-edge 250-bed quaternary care hospital in Pune, the first phase of planned capacity of 400 beds. The new facility integrates advanced surgical robotics, precision oncology, comprehensive critical care with 100+ ICU beds, and multidisciplinary programs with IoT-enabled monitoring and digital health tools that strengthen care continuity, positioning the centre as a regional reference centre for complex, tech-enabled care in Western India.

### **Leadership in Transplant Care**

Apollo Hospitals sustained its position as the world's busiest solid organ transplant program. At its flagship Chennai hospital, a bilateral lung transplant was completed using a multi-modal green corridor, including metro-rail organ transport a first in Tamil Nadu. In Trichy, a liver transplant succeeded with the donor organ transported 190 km in 2.5 hours without a green corridor, demonstrating exceptional planning. In Bengaluru, metro rail infrastructure enabled the rapid transfer of a live heart in just 20 minutes, ensuring lifesaving timing.

### **Rising Footprint in Bone Marrow Transplantation**

Apollo Hospitals, Kolkata, completed 48 bone marrow transplants in YTD Dec FY26, with ~50% international cases, reinforcing the Group's growing global reputation in advanced haematology care.

# Apollo Hospitals Q3FY26 Results

## Q3FY26 Consolidated Results

**Q3 Consolidated Revenue grew 17% YoY to Rs. 6,477 Crore**

**Q3 Consolidated EBITDA grew 27% YoY to Rs. 965 Crore**

**Q3 Consolidated PAT grew 35% YoY to Rs. 502 Crore**

## YTD Dec FY26 Consolidated Results

**YTD Dec FY26 Consolidated Revenue grew 15% YoY to Rs. 18,623 Crore**

**YTD Dec FY26 Consolidated EBITDA grew 22% YoY to Rs. 2,758 Crore**

**YTD Dec FY26 Consolidated PAT grew 34% YoY to Rs. 1,412 Crore**

**Dr. Prathap C Reddy, Chairman, Apollo Hospitals Enterprise Ltd.** said, "Q3FY26 reflects the fundamental strength and clinical depth of Apollo's integrated care model. Across our network, teams are consistently delivering strong outcomes through disciplined execution in patient safety, quality, and experience. This quarter, sustained investments in advanced clinical capability translated into meaningful progress across key specialties from Apollo OMR completing 150 robotic joint replacement surgeries in its first 150 days, to the expansion of our stroke care network in Chennai with nine advanced stroke labs, strengthening rapid-access care and outcomes.

We further reinforced our differentiated leadership in neurosciences with the launch of a dedicated Centre of Excellence for Parkinson's disease and Deep Brain Stimulation care in Chennai, strengthened comprehensive oncology care through the 'Save My Stomach' early detection programme at Apollo Cancer Centres, and expanded high-acuity capability with a dedicated heart and lung transplant unit in Karnataka. In parallel, partnerships such as the MoU with Coal India reflect Apollo's vision to expand access to standardized, high-quality healthcare by building integrated preventive and tertiary care pathways for large workforce populations.

Apollo's transplant programme reflects the depth, scale, and discipline of our clinical systems. As one of the world's busiest solid organ transplant programmes, our teams now perform an average of five solid organ transplants each day. Cumulatively, we have completed more than 21,000 kidney transplants and over 5,000 liver transplants—becoming the first hospital group in India and the region to reach this landmark—along with 159 heart transplants and 232 lung transplants. These outcomes are the result of standardized clinical pathways, multidisciplinary expertise, and a sustained commitment to patient safety, ethics, and long-term outcomes.

The Union Budget provides an important tailwind to India's aspiration to become a global destination for healthcare. The proposal to support states in establishing five regional medical hubs through public-private partnership is a strategic step toward building a high-quality, well-coordinated Medical Value Travel ecosystem.

At Apollo, we view Medical Value Travel as a long-term national mission that reflects India's depth of clinical expertise, outcomes excellence, and cost advantage. We will continue to work closely with policymakers and state partners to strengthen international patient pathways, expand high-acuity capacity, and ensure seamless coordination across pre-travel evaluation, clinical care, and post-discharge follow-up."

## Financial Performance – Q3FY26

### **Consolidated Q3FY26 Performance**

- Revenue at Rs. 6,477 crore vs Rs. 5,527 crore in Q3FY25; growth of 17% YoY
- EBITDA at Rs. 965 crore vs Rs. 762 crore in Q3FY25. This is after Apollo 24/7 cost of Rs. 124 crore in the quarter (incl. Rs. 38 crore non-cash ESOP charge) vs Rs. 141 crore in Q3FY25.
- Reported PAT at Rs. 502 crore vs Rs. 372 crore in Q3FY25
- Diluted EPS of Rs. 34.94 per share in Q3FY26 (not annualized)
- GMV of Apollo 24/7 at Rs. 525 Crore

### **Healthcare service Q3FY26 Performance**

- Revenue at Rs. 3,183 crore vs Rs. 2,785 crore in Q3FY25; growth of 14% YoY
- EBITDA grew 18% at Rs. 790 crore vs Rs. 671 crore in Q3FY25; Margins at 24.8% in Q3FY26
- PAT stood at Rs. 422 crore vs Rs. 348 crore in Q3FY25, up 21% YoY

### **Apollo Health and Lifestyle Limited Q3FY26 Performance**

- Revenue at Rs. 467 crore vs Rs. 390 crore in Q3FY25; growth of 20% YoY
- EBITDA grew 39% at Rs. 48 crore vs Rs. 34 crore in Q3FY25; Margins at 10.2% in Q3FY26
- PAT loss of Rs. 6 crore vs loss of Rs. 8 crore in Q3FY25

### **Apollo HealthCo Q3FY26 Performance**

- Revenue at Rs. 2,827 crore vs Rs. 2,352 crore in Q3FY25; growth of 20% YoY
- EBITDA at Rs. 128 crore vs Rs. 57 crore in Q3FY25; Margins at 4.5% in Q3FY26
- PAT stood at Rs. 87 crore vs Rs. 32 crore in Q3FY25

## Financial Performance – YTD Dec FY26

### **Consolidated YTD Dec FY26 Performance**

- Revenue at Rs. 18,623 crore vs Rs. 16,202 crore in YTD Dec FY25; growth of 15% YoY
- EBITDA at Rs. 2,758 crore vs Rs. 2,252 crore in YTD Dec FY25. This is after Apollo 24/7 cost of Rs. 371 crore in YTD Dec FY26 (incl. Rs. 95 crore non-cash ESOP charge) vs Rs. 425 crore in YTD Dec FY25.
- Reported PAT at Rs. 1,412 crore vs Rs. 1,056 crore in YTD Dec FY25
- Diluted EPS of Rs. 98.23 per share in YTD Dec FY26 (not annualized)
- GMV of Apollo 24/7 at Rs. 1,508 Crore

### **Healthcare service YTD Dec FY26 Performance**

- Revenue at Rs. 9,287 crore vs Rs. 8,326 crore in YTD Dec FY25; growth of 12% YoY
- EBITDA grew 14% at Rs. 2,289 crore vs Rs. 2,014 crore in YTD Dec FY25; Margins at 24.6% in YTD Dec FY26
- PAT stood at Rs. 1,216 crore vs Rs. 1,041 crore in YTD Dec FY25, up 17% YoY

### **Apollo Health and Lifestyle Limited YTD Dec FY26 Performance**

- Revenue at Rs. 1,376 crore vs Rs. 1,160 crore in YTD Dec FY25; growth of 19% YoY
- EBITDA grew 29% at Rs. 138 crore vs Rs. 107 crore in YTD Dec FY25; Margins at 10.0% in YTD Dec FY26
- PAT loss of Rs. 20 crore vs loss of Rs. 23 crore in YTD Dec FY25

### **Apollo HealthCo YTD Dec FY26 Performance**

- Revenue at Rs. 7,960 crore vs Rs. 6,717 crore in YTD Dec FY25; growth of 19% YoY
- EBITDA at Rs. 332 crore vs Rs. 131 crore in YTD Dec FY25; Margins at 4.2% in YTD Dec FY26
- PAT stood at Rs. 217 crore vs Rs. 38 crore in YTD Dec FY25

## **Q3 FY26 Segment-wise Performance Update**

### **Healthcare Services (Hospitals)**

As on December 31, 2025, Apollo Hospitals had 8,072 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 67% in Q3FY26 vs 68% in the same period in the previous year.

Consolidated Revenue of the healthcare services division grew 14% to Rs.3,183 crore in Q3FY26 compared to Rs.2,785 crore in Q3FY25.

EBITDA (Post Ind AS 116) was at Rs. 790 crore in Q3FY26 compared to Rs. 671 crore in Q3FY25. EBITDA, higher by 18% YoY.

Revenue in the Tamil Nadu cluster grew 14%, IP Volumes grew 6%. ARPP grew 9% to Rs. 2,02,804. Overall occupancy in the cluster was 1,355 beds (68% occupancy) as compared to 1,305 beds (64% occupancy) in the previous year.

In AP Telangana region, Revenue grew 16%, IP volumes grew 12%. ARPP grew 6% to Rs. 1,91,456. Occupancy in the cluster was 845 beds (65% occupancy) as compared to 815 beds (66% occupancy) in the previous year.

In Karnataka region, Revenue grew 16%, IP volumes degrew 1%. ARPP grew 18% to Rs. 1,91,388. Occupancy in the cluster was 520 beds (67% occupancy) as compared to 549 beds (71% occupancy) in the previous year.

In Eastern region, Revenue grew 15%, IP volumes grew 6%. ARPP grew 10% to Rs. 1,54,408. Occupancy in the cluster was 1,383 beds (76% occupancy) as compared to 1,349 beds (72% occupancy) in the previous year.

In Western region, Revenue grew 17%, IP volumes grew 6%. ARPP grew 12% to Rs. 1,66,264. Occupancy in the cluster was 492 beds (51% occupancy) as compared to 499 beds (57% occupancy) in the previous year.

In Northern region, Revenue grew 12%, IP volumes degrew 4%. ARPP grew 16% to Rs.1,75,836. Occupancy in the cluster was 821 beds (67% occupancy) as compared to 885 beds (74% occupancy) in the previous year.

### **Apollo Health and Lifestyle Limited: Diagnostics and Retail Healthcare**

- AHLL Gross Revenue at Rs. 467 crore; up 20% YoY
- Diagnostics Revenue stood at Rs. 177 crore, Primary Care at Rs. 128 crore, Specialty Care at Rs. 184 crore.

## Apollo HealthCo: Digital Healthcare and Omni-channel Pharmacy platform

- Overall Health Co Revenue were at Rs. 2,827 crore vs Rs. 2,352 crore in Q3FY25 representing 20% YoY growth.
- Offline Pharmacy distribution Revenue were at Rs. 2,511 crore vs Rs. 2,079 crore in Q3FY25 while Revenue from Digital platform were at Rs. 316 crore vs Rs. 274 crore in Q3FY25.
- 185 net new stores were opened in this quarter, taking the total number to 7,113 stores.
- GMV of Apollo 24/7 at Rs. 525 crore in Q3 FY26, growth of 28% over Q3FY25.
- Avg Q3FY26 run rate of 57K/day order across Pharma, Diagnostics Consultations (excluding IP/OP referrals) compared to 50K/day in Q3FY25.

## Clinical Excellence Highlights

### Transformational Paediatric Breakthrough

Apollo Children's Hospital, Chennai, achieved a significant milestone by treating a 13-month-old with Spinal Muscular Atrophy (Type 1) using gene therapy. Within one month, the child showed notable gains in motor control, vocalisation and feeding ability outcomes absent before therapy, showcasing Apollo's ability to translate cutting-edge science into life-changing results.

### Chennai

- Apollo Main hospital – Greams Road Chennai: State-first clinical innovation: Successfully performed Tamil Nadu's first dual-chamber leadless pacemaker implantation, delivering a minimally invasive, physiologic pacing solution for high-risk cardiac patients.
- Apollo Main hospital – Greams Road Chennai: Launch of Tamil Nadu's first centre of excellence for Parkinson's disease and deep brain stimulation
- Apollo Chennai City: Tamil Nadu's Largest Stroke Network, Apollo Hospitals Chennai Expands Stroke Care Across the City - a comprehensive, protocol-driven system designed to ensure rapid diagnosis and treatment for stroke patients across the city.

### Bangalore

Apollo Hospitals - BG Road, Bangalore: System productivity benchmark: Achieved the highest monthly robotic throughput on a single Da Vinci system—61 procedures in December, performed by 12 surgeons.

### Hyderabad

Apollo Hospitals - JH, Hyderabad: Global surgeon productivity milestone: Dr. Nagesh Ayalasomayajula became internationally the fastest to complete 50 robotic cardiac surgeries post-certification, achieving the milestone within just 3 months.

### Lucknow

Apollo Medics Hospitals, Lucknow: Dual-chamber leadless pacemaker implantation was successfully performed for a patient. This was the first of its kind procedure in the state of Uttar Pradesh.

## Guwahati

Apollo Excelcare Hospital, Guwahati: Achieved a major medical milestone by successfully performing the first-ever combined Transcatheter Aortic Valve Implantation (TAVI) and angioplasty in the Northeast. This landmark achievement marks a major leap forward in advanced cardiac care access for patients in the region.

## New Launches, Initiatives And Partnerships

- Apollo Hospitals opens 250-bed facility in Pune, 3rd in Maharashtra
- Apollo Spectra Hospital, Delhi launched an advanced multi-robot surgery centre equipped with cutting-edge robotic systems and personalised 3D surgical planning.
- Apollo Children's Hospital, in association with the Apollo Shine Foundation, launched "Happy Hearts", an initiative aimed at encouraging empathy and emotional healing among children.
- Apollo Cancer Centres Launches 'Save My Stomach' Early Detection Program to Combat the silent Threat of Stomach Cancer.
- Apollo launched a dedicated Centre of Excellence for Parkinson's & DBS care in Chennai
- Apollo Hospitals signed a MoU with Coal India to expand healthcare access

## Corporate Social Responsibility

During Q3 FY 2025–26, the Apollo Foundation continued to scale its preventive and community healthcare initiatives, strengthening reach while maintaining delivery quality and sustainability. Through its flagship **Billion Hearts Beating (BHB)** and **Total Health (TH)** programmes, the Foundation reached a total of **276,369 beneficiaries** during the quarter.

BHB reached **144,781 individuals**, with a significant scale-up in December, while TH engaged **131,588 individuals** with consistent month-on-month performance. During the quarter, **BHB, TH and SACHI** worked in close alignment to enhance operational efficiency, deepen community partnerships, and strengthen long-term impact through technology-enabled and outcome-driven models.

## Awards And Accolades

### **Southern Region**

- **Apollo Hospitals, Chennai (Main) - Economic Times Award 2025 in 5 categories** - Multi - Specialty Hospital of the Year – National, Hospital of the Year - Emergency and Trauma Care – National; Hospital of the Year - Nursing Excellence – National; Hospital of the year – Neurology – National; Hospital of the year – Vascular Surgery – Zonal (South)  
**CII TN Healthcare Excellence Honours'25 in 2 categories** - Gastroenterology; Geriatrics
- **Apollo Cancer Institute, Teynampet – AHPI Award for Excellence in Healthcare 2026** Excellence in Quality - Beyond Accreditation
- **Apollo Children's hospital - CII Tamilnadu Medclave Awards 5th edition Oct 2025** - Best Paediatric Cardiology, Nursing Excellence Award  
**AHPI Tamilnadu Excellence Awards 2025**- Best Multi-Speciality Hospital
- **Apollo Women's hospital - CII Tamilnadu Medclave Awards 5th edition Oct 2025** - Best Obstetrics & Gynaecology Hospital. **CII Tamilnadu Medclave Awards 5th edition Oct 2025** - Nursing Excellence Award  
**CII Tamilnadu Medclave Awards 5th edition Oct 2025** - Nursing Excellence Award
- **Apollo Specialty Hospitals, Madurai** - CII Energy Efficiency Award

### **AP & Telangana**

- **Apollo Health City, Jubilee Hills - Healthcare Management Awards 2025** by HYBRIZ TV.  
 Best Multispeciality Hospitals Awards by **THE WEEK Health Summit 2025**.  
**Healthcare Professionals Safety and Protection in OR Environment "i Protect Conclave"** by Consortium of Accredited Healthcare Organizations (CAHO)
- **Apollo Hospitals, Vizag new** - Excellence in Cardiac Care (South)- **FE Healthcare Summit**  
 Excellence in Emergency & Critical Care (South)- - **FE Healthcare Summit**  
 Excellence in Oncology, Orthopaedic Care (South) - **FE Healthcare Summit**

### **Karnataka**

- **Apollo BGS Hospitals, Mysore** - Cardiac Hospital of the Year South by **Voice of Health care**  
 Dr.Rajkumar .P.Wadhwa.HOD & Chief of Gastroenterology honoured by **Master of ISG 2025** by Indian society of Gastroenterology  
 HR & Operational excellence awards 2025 -Mysore **CHRO Forum (HR DASARA 2025)**
- **Apollo Hospital, Jayanagar** - **News 18 Healthcare Excellence Awards**  
 Dr.Pradeep Kocheepan - Health Excellence & Conclave Excellence In Orthopaedic Sports Medicine

### **Northern Region**

- **Indraprastha Apollo Hospitals, Delhi** - **IHF Awards 2025- Nov 2025**  
 Honorable Mention for the Excellence Award for Healthcare Workers' Wellbeing  
 The Week- November 2025 - Best multispecialty hospital
- **Apollo medics Super Speciality Hospitals, Lucknow**  
 Best Hospital in Lucknow - The Week  
 Top Emerging Hospital of India - The Week

## Western Region

- **Apollo Hospitals, Navi Mumbai** - Sustainable and eco-conscious practices in healthcare and hospital operations from **Health & Environment Leadership Platform - Maharashtra - Oct 2025**
- **Apollo Hospitals, Ahmedabad** - **The WEEK Hansa (Rank No.2)**  
**Best Multispecialty Hospitals** - Nov 25;  
**AHPI Award for Excellence in Nursing Practices** - 2026

## Eastern Region

- **Apollo Hospitals, Bhubaneshwar** - Best Patient Centric Hospital, OTV Business Odisha Award 2025  
Runner up, Healthcare Organisation Early Technology Adoption Award by CAHO @CAHOTECH 2025
- **Apollo Hospitals Guwahati** - **Economic Times Healthcare Award 2025 in 2 categories** - Hospital of the Year - Gastroenterology (Regional), Hospital of the Year - Critical care (Regional)  
**AHPI Award - Association of Healthcare Providers (India) Awards for Excellence in Healthcare 2026-**  
i) Excellence in Nursing Services ii) Digital Excellence Award
- **Excelcare, Guwahati - ICN** - Received winner prize for **Vanguard of Patient Safety Award on Surgical safety** - Nursing Luminaries Conclave

## **About Apollo**

*Apollo revolutionized healthcare when Dr. Prathap Reddy opened the first hospital in Chennai in 1983. Today, Apollo is the world's largest integrated healthcare platform with over 10,300 beds across 76 hospitals, 7,100+ pharmacies, 300+ clinics, 2,450+ diagnostic centers. It is one of the world's leading cardiac centers, having performed over 3,00,000 angioplasties and 2,00,000 surgeries. Apollo continues to invest in research and innovation to bring the most cutting-edge technologies, equipment, and treatment protocols to ensure patients have access to the best care in the world. Apollo's 1,20,000 family members are dedicated to delivering exceptional care and leaving the world better than we found it.*

For further details, log onto: [www.apollohospitals.com](http://www.apollohospitals.com)

For further information, please contact:

### **For Media / Investors**

R Krishnakumar  
Apollo Hospitals Ltd.  
[Krishnakumar\\_r@apollohospitals.com](mailto:Krishnakumar_r@apollohospitals.com)  
+91 44 2829 7840

Mayank Vaswani  
CDR India  
[mayank@cdr-india.com](mailto:mayank@cdr-india.com)  
+91 22 6645 1230

### **Disclaimer**

*Some of the statements in this document that are not historical facts are forward looking statements. These forward-looking statements include our financial and growth projections as well as statements concerning our plans, strategies, intentions and beliefs concerning our business and the markets in which we operate.*

*These statements are based on information currently available to us, and we assume no obligation to update these statements as circumstances change. There are risks and uncertainties that could cause actual events to differ materially from these forward-looking statements. These risks include, but are not limited to, the level of market demand for our services, the highly-competitive market for the types of services that we offer, market conditions that could cause our customers to reduce their spending for our services, our ability to create, acquire and build new businesses and to grow our existing businesses, our ability to attract and retain qualified personnel, currency fluctuations and market conditions in India and elsewhere around the world, and other risks not specifically mentioned herein but those that are common to industry.*

*Further, this document may make references to reports and publications available in the public domain. Apollo Hospitals Enterprise Ltd. makes no representation as to their accuracy or that the company subscribes to those views / findings.*